Health Care Without Harm aims to transform global healthcare to minimize its environmental impact and promote sustainability. Lorna Rothery spoke to the team about the effects of pharmaceutical pollution and the necessity for the industry to adopt greener practices.
Dr. Christian Löfke, researcher and product developer at BioBloom in Austria explains why hemp protein is gaining a reputation as nutraceutical product.
CBD oil has long been utilised for its various therapeutic effects, but what about its effect on cancer? Read on to find out more about what the research shows.
Dr Andrew McIndoe MBE & Dr Ed Hammond MBE chart the rapid and successful adaptation of delivery of a national teaching programme to the COVID-19 pandemic.
Aida Batista, Vice President of the European Association of Hospital Pharmacists (EAHP), explores if we can live without pharmacology, including comment on the use of opioid and sedative drugs.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the Pfizer/BioNTech COVID-19 vaccine for use in the UK and will be made available as early as next week.
Roxane Feller, Secretary General of AnimalhealthEurope, sheds light on One Health – the only way forward that includes comment on veterinary medicines.
Andreas Met, COO, Compliance and Director at Halo Labs highlights how the use of medical cannabis is on the rise in the UK and could offer relief to many NHS patients.
Gino Martini, RPS Chief Scientist and the Science and Research Team at the Royal Pharmaceutical Society reflect on the role of pharmacy during COVID-19 in delivering accessible, safe and effective care for all.
Professor Mike Barnes, Co-Founder of Maple Tree Consultancy states that the UK’s clinicians need training in medical cannabis and explains precisely why this should be.
Hannah Deacon, Co-Founder of Maple Tree Consultancy and Campaigner ponders if the UK’s post-COVID-19 economy can benefit from a booming medical cannabis industry.
Rex Clements, CEO at Centrient Pharmaceuticals, discusses how the upcoming EU Pharma Strategy can prevent shortages and strengthen Europe’s manufacturing base, especially for antibiotics.
